Review Article
Full Access
Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials
David T. Felson Md, Mph,
Jennifer J. Anderson PhD,
Robert F. Meenan Md, Mph,
Corresponding Author
David T. Felson Md, Mph
Associate Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Arthritis Center, A-203, Boston University School of Medicine, 80 E. Concord Street, Boston, MA 02118Search for more papers by this authorJennifer J. Anderson PhD
Associate Research Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Search for more papers by this authorRobert F. Meenan Md, Mph
Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Search for more papers by this authorDavid T. Felson Md, Mph,
Jennifer J. Anderson PhD,
Robert F. Meenan Md, Mph,
Corresponding Author
David T. Felson Md, Mph
Associate Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Arthritis Center, A-203, Boston University School of Medicine, 80 E. Concord Street, Boston, MA 02118Search for more papers by this authorJennifer J. Anderson PhD
Associate Research Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Search for more papers by this authorRobert F. Meenan Md, Mph
Professor of Medicine
Arthritis Center, Boston University School of Medicine, and the Departments of Medicine, Boston City Hospital and University Hospital, Boston, Massachusetts.
Search for more papers by this author
References
- 1 Iannuzzi L, Dawson N, Zein N, Kushner I: Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 309: 1023–1028, 1983
- 2 Cupples LA, Heeren T, Schatzkin A, Colton T: Multiple testing of hypotheses in comparing two groups. Ann Intern Med 100: 122–129, 1984
- 3 Smith DG, Clemens J, Crede W, Harvey M, Gracely EJ: Impact of multiple comparisons in randomized clinical trials. Am J Med 83: 545–550, 1987
- 4 Anderson JJ, Felson DT, Meenan RF, Williams HJ: Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 32: 1093–1099, 1989
- 5 Lansbury J: Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis: theoretic and clinical considerations. Arthritis Rheum 1: 505–522, 1958
- 6 Smythe HA, Helewa A, Goldsmith CH: Selection and combination of outcome measures. J Rheumatol 9: 770–774, 1982
- 7 Bombardier C, Tugwell P: A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 9: 753–757, 1982
- 8 Simon R: Confidence intervals for reporting results of clinical trials. Ann Intern Med 105: 429–435, 1986
- 9 Grossman SA, Burch PA: Quantification of tumor response to anti-neoplastic therapy. Semin Oncol 15: 441–454, 1988
- 10 Pinals RS, Masi AT, Larsen RA,and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24: 1308–1315, 1981
- 11 Ward JR, Williams HJ, Boyce E, Egger MJ, Reading JC, Samuelson CO: Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses. Symposium on oral gold therapy in rheumatoid arthritis: auranofin, San Francisco, 1982. Am J Med 75 (suppl): 133–137, 1983
- 12 Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Altz-Smith M, Samuelson CO Jr, Willkens RF, Solsky MA, Hayes SP, Blocka KL, Weinstein A, Meenan RF, Guttadauria M, Kaplan SB, Klippel J: Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 26: 1303–1315, 1983
- 13 Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger MJ, Reading JC, Ward JR: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 28: 721–730, 1985
- 14 Pinals RS, Kaplan SB, Lawson JG, Hepburn B: Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 29: 1427–1434, 1986
- 15 Hochberg MC: Auranofin or D-penicillamine in the treatment of rheumatoid arthritis. Ann Intern Med 105: 528–535, 1986
- 16 Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM: Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 27: 267–276, 1984
- 17 Taggart AJ, Hill J, Astbury C, Dixon JS: Sulphasalazine alone or in combination with d-penicillamine in rheumatoid arthritis. Br J Rheumatol 26: 37–39, 1987
- 18 Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL,and the Auranofin Cooperating Group: Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trials. Am J Med 81: 565–578, 1986
- 19 Suarez-Almazor ME, Fitzgerald AV, Grace M, Russell AS: A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate in the treatment of rheumatoid arthritis. J Rheumatol 15: 753–756, 1988
- 20 Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818–822, 1985
- 21 Hamdy H, McKendry RJR, Mierins E, Liver JA: Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four-week controlled clinical trial. Arthritis Rheum 30: 361–368, 1987
- 22 Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103: 489–496, 1985
- 23 Manthorpe R, Horbov S, Sylvest J, Vinterberg H: Auranofin versus penicillamine in rheumatoid arthritis: one-year results from a prospective clinical investigation. Scand J Rheumatol 15: 13–22, 1986
- 24 Hutchinson TA, Boyd NF, Feinstein AR: Scientific problems in clinical scales, as demonstrated in the Karnofsky Index of Performance Status. J Chronic Dis 32: 661–666, 1979
- 25
Evans C,
McCarthy M:
Prognostic uncertainty in terminal care: can the Karnofsky Index help?
Lancet
I:
1204–1206,
1985
10.1016/S0140-6736(85)92876-4 Google Scholar
- 26 Meenan RF, Anderson JJ, Kazis LE, Egger MJ, Altz-Smith M, Samuelson CO Jr, Willkens RF, Solsky MA, Hayes SP, Blocka KL, Weinstein A, Guttadauria M, Kaplan SB, Klippel J: Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure. Arthritis Rheum 27: 1344–1352, 1984
- 27 Thomas MH, Rothermich NO, Philips VK, Bergen W, Hedrick SW: Gold vs D-penicillamine double blind study and followup. J Rheumatol 11: 764–767, 1984
- 28 Capell HA, Hunter JA, Rennie JA, Murdoch RM: Levamisole—a possible alternative to gold and penicillamine in the longterm treatment of rheumatoid arthritis? J Rheumatol 8: 730–740, 1981
- 29 Davis P, Menard H, Thompson J, Harth M, Beaudet F: One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. J Rheumatol 12: 60–67, 1985
- 30 Menard HA, Beaudet F, Davis P, Harth M, Percy JS, Russell AS, Thompson JM: Gold therapy in rheumatoid arthritis: interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol [Suppl] 9: 179–183, 1982
- 31 Barraclough D, Brook A, Brooks P, Boyden K, Thomas D, Tymms K: A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report. J Rheumatol [Suppl] 9: 197–200, 1982
- 32 Smith PR, Brown GMM, Meyers OL: An open comparative study of auranofin vs. gold sodium thiomalate. J Rheumatol [Suppl] 9: 190–196, 1982
- 33 Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, Weisman MH, Schlegel S, Michaels RM, Luggen ME, Polisson RP, Singer JZ, Kantor SM, Shiroky JB, Gomez MI, Reading JC, Egger MJ: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 31: 702–713, 1988
- 34 Schattenkirchner M, Kaik B, Muller-Fassbender H, Rau R, Zeidler H: Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis: a double-blind, comparative multicenter study. J Rheumatol [Suppl] 9: 184–189, 1982
- 35 Felson DT, Anderson JJ, Meenan RF: Comparing the efficacy of remittive agents in rheumatoid arthritis (abstract). Arthritis Rheum 32 (suppl 4): S118, 1989
- 36 Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC: Meta-analyses of randomized controlled trials. N Engl J Med 316: 450–455, 1987
- 37 Ratain JS, Hochberg MC: Clinical trials: a guide to understanding methodology and interpreting results. Arthritis Rheum 33: 131–139, 1990
- 38 Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambrox A: A method for assessing the quality of a randomized control trial. Controlled Clin Trials 2: 31–49, 1981
- 39 DerSimonian R, Charette LJ, McPeek B, Mosteller F: Reporting on methods in clinical trials. N Engl J Med 306: 1332–1337, 1982
